Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults
- Autores
- Algorta, Jaime; Kepha, Stella; Krolewiecki, Alejandro Javier; Li, Hanbin; Giang, Justin; Fleitas, Pedro; Mwandawiro, Charles; Muñoz, José
- Año de publicación
- 2024
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Trichuris trichiura is a soil-transmitted helminth causing intestinal disease. Albendazole is the standard treatment despite its moderate efficacy, which is improved when co-administered with ivermectin. A fixeddose combination adds practical advantages mainly for mass drug administration. The aim of this article is to define the population pharmacokinetic models and exposure–response of an innovative albendazole/ivermectin combination. Data were obtained from a phase I clinical trial in healthy adults and from a phase II trial in children and adolescents infected with T.trichiura. Nonlinear mixed-effects models were built for albendazole and ivermectin using NONMEM®. Area under the curve was calculated using the empirical Bayes estimates of the pharmacokinetic parameters of each individual and used for evaluation of exposure–response between cure rate and pharmacokinetic exposure. The pharmacokinetics of albendazole was described using a two-compartmental model with first-order absorption and the pharmacokinetics of ivermectin was described using a twocompartmental model with zero-order followed by first-order absorption. Clearance and volume of distribution increased with body weight for both albendazole and ivermectin. Day 1 area under the curve of albendazole and ivermectin from the children and adolescents treated with the combination regimens were similar to the healthy adults treated with control drugs. A flat exposure–response relationship was observed between the cure rate and drug exposure. Population pharmacokinetic of a combination of albendazole and ivermectin in children, adolescents, and adults, either healthy or infected by T.trichiura was described. The dosage selected in the phase II trial was appropriate for the subsequent phase III.
Fil: Algorta, Jaime. Liconsa Sa; España
Fil: Kepha, Stella. Kenya Medical Research Institute; Kenia
Fil: Krolewiecki, Alejandro Javier. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina
Fil: Li, Hanbin. Quantx Consulting; Estados Unidos
Fil: Giang, Justin. Quantx Consulting; Estados Unidos
Fil: Fleitas, Pedro. Universidad de Barcelona; España
Fil: Mwandawiro, Charles. Kenya Medical Research Institute; Kenia
Fil: Muñoz, José. Universidad de Barcelona; España - Materia
-
ALBENDAZOLE
IVERMECTIN
POP-PK
SOIL TRANSMITTED HELMINTHS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/247200
Ver los metadatos del registro completo
id |
CONICETDig_6a307615067aa7619d8a6b084fc2eb50 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/247200 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and AdultsAlgorta, JaimeKepha, StellaKrolewiecki, Alejandro JavierLi, HanbinGiang, JustinFleitas, PedroMwandawiro, CharlesMuñoz, JoséALBENDAZOLEIVERMECTINPOP-PKSOIL TRANSMITTED HELMINTHShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Trichuris trichiura is a soil-transmitted helminth causing intestinal disease. Albendazole is the standard treatment despite its moderate efficacy, which is improved when co-administered with ivermectin. A fixeddose combination adds practical advantages mainly for mass drug administration. The aim of this article is to define the population pharmacokinetic models and exposure–response of an innovative albendazole/ivermectin combination. Data were obtained from a phase I clinical trial in healthy adults and from a phase II trial in children and adolescents infected with T.trichiura. Nonlinear mixed-effects models were built for albendazole and ivermectin using NONMEM®. Area under the curve was calculated using the empirical Bayes estimates of the pharmacokinetic parameters of each individual and used for evaluation of exposure–response between cure rate and pharmacokinetic exposure. The pharmacokinetics of albendazole was described using a two-compartmental model with first-order absorption and the pharmacokinetics of ivermectin was described using a twocompartmental model with zero-order followed by first-order absorption. Clearance and volume of distribution increased with body weight for both albendazole and ivermectin. Day 1 area under the curve of albendazole and ivermectin from the children and adolescents treated with the combination regimens were similar to the healthy adults treated with control drugs. A flat exposure–response relationship was observed between the cure rate and drug exposure. Population pharmacokinetic of a combination of albendazole and ivermectin in children, adolescents, and adults, either healthy or infected by T.trichiura was described. The dosage selected in the phase II trial was appropriate for the subsequent phase III.Fil: Algorta, Jaime. Liconsa Sa; EspañaFil: Kepha, Stella. Kenya Medical Research Institute; KeniaFil: Krolewiecki, Alejandro Javier. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; ArgentinaFil: Li, Hanbin. Quantx Consulting; Estados UnidosFil: Giang, Justin. Quantx Consulting; Estados UnidosFil: Fleitas, Pedro. Universidad de Barcelona; EspañaFil: Mwandawiro, Charles. Kenya Medical Research Institute; KeniaFil: Muñoz, José. Universidad de Barcelona; EspañaNature Publishing Group2024-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/247200Algorta, Jaime; Kepha, Stella; Krolewiecki, Alejandro Javier; Li, Hanbin; Giang, Justin; et al.; Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults; Nature Publishing Group; Clinical Pharmacology & Therapeutics; 2024; 9-2024; 1-110009-9236CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3424info:eu-repo/semantics/altIdentifier/doi/10.1002/cpt.3424info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:59:29Zoai:ri.conicet.gov.ar:11336/247200instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:59:29.391CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults |
title |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults |
spellingShingle |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults Algorta, Jaime ALBENDAZOLE IVERMECTIN POP-PK SOIL TRANSMITTED HELMINTHS |
title_short |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults |
title_full |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults |
title_fullStr |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults |
title_full_unstemmed |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults |
title_sort |
Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults |
dc.creator.none.fl_str_mv |
Algorta, Jaime Kepha, Stella Krolewiecki, Alejandro Javier Li, Hanbin Giang, Justin Fleitas, Pedro Mwandawiro, Charles Muñoz, José |
author |
Algorta, Jaime |
author_facet |
Algorta, Jaime Kepha, Stella Krolewiecki, Alejandro Javier Li, Hanbin Giang, Justin Fleitas, Pedro Mwandawiro, Charles Muñoz, José |
author_role |
author |
author2 |
Kepha, Stella Krolewiecki, Alejandro Javier Li, Hanbin Giang, Justin Fleitas, Pedro Mwandawiro, Charles Muñoz, José |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
ALBENDAZOLE IVERMECTIN POP-PK SOIL TRANSMITTED HELMINTHS |
topic |
ALBENDAZOLE IVERMECTIN POP-PK SOIL TRANSMITTED HELMINTHS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Trichuris trichiura is a soil-transmitted helminth causing intestinal disease. Albendazole is the standard treatment despite its moderate efficacy, which is improved when co-administered with ivermectin. A fixeddose combination adds practical advantages mainly for mass drug administration. The aim of this article is to define the population pharmacokinetic models and exposure–response of an innovative albendazole/ivermectin combination. Data were obtained from a phase I clinical trial in healthy adults and from a phase II trial in children and adolescents infected with T.trichiura. Nonlinear mixed-effects models were built for albendazole and ivermectin using NONMEM®. Area under the curve was calculated using the empirical Bayes estimates of the pharmacokinetic parameters of each individual and used for evaluation of exposure–response between cure rate and pharmacokinetic exposure. The pharmacokinetics of albendazole was described using a two-compartmental model with first-order absorption and the pharmacokinetics of ivermectin was described using a twocompartmental model with zero-order followed by first-order absorption. Clearance and volume of distribution increased with body weight for both albendazole and ivermectin. Day 1 area under the curve of albendazole and ivermectin from the children and adolescents treated with the combination regimens were similar to the healthy adults treated with control drugs. A flat exposure–response relationship was observed between the cure rate and drug exposure. Population pharmacokinetic of a combination of albendazole and ivermectin in children, adolescents, and adults, either healthy or infected by T.trichiura was described. The dosage selected in the phase II trial was appropriate for the subsequent phase III. Fil: Algorta, Jaime. Liconsa Sa; España Fil: Kepha, Stella. Kenya Medical Research Institute; Kenia Fil: Krolewiecki, Alejandro Javier. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina Fil: Li, Hanbin. Quantx Consulting; Estados Unidos Fil: Giang, Justin. Quantx Consulting; Estados Unidos Fil: Fleitas, Pedro. Universidad de Barcelona; España Fil: Mwandawiro, Charles. Kenya Medical Research Institute; Kenia Fil: Muñoz, José. Universidad de Barcelona; España |
description |
Trichuris trichiura is a soil-transmitted helminth causing intestinal disease. Albendazole is the standard treatment despite its moderate efficacy, which is improved when co-administered with ivermectin. A fixeddose combination adds practical advantages mainly for mass drug administration. The aim of this article is to define the population pharmacokinetic models and exposure–response of an innovative albendazole/ivermectin combination. Data were obtained from a phase I clinical trial in healthy adults and from a phase II trial in children and adolescents infected with T.trichiura. Nonlinear mixed-effects models were built for albendazole and ivermectin using NONMEM®. Area under the curve was calculated using the empirical Bayes estimates of the pharmacokinetic parameters of each individual and used for evaluation of exposure–response between cure rate and pharmacokinetic exposure. The pharmacokinetics of albendazole was described using a two-compartmental model with first-order absorption and the pharmacokinetics of ivermectin was described using a twocompartmental model with zero-order followed by first-order absorption. Clearance and volume of distribution increased with body weight for both albendazole and ivermectin. Day 1 area under the curve of albendazole and ivermectin from the children and adolescents treated with the combination regimens were similar to the healthy adults treated with control drugs. A flat exposure–response relationship was observed between the cure rate and drug exposure. Population pharmacokinetic of a combination of albendazole and ivermectin in children, adolescents, and adults, either healthy or infected by T.trichiura was described. The dosage selected in the phase II trial was appropriate for the subsequent phase III. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/247200 Algorta, Jaime; Kepha, Stella; Krolewiecki, Alejandro Javier; Li, Hanbin; Giang, Justin; et al.; Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults; Nature Publishing Group; Clinical Pharmacology & Therapeutics; 2024; 9-2024; 1-11 0009-9236 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/247200 |
identifier_str_mv |
Algorta, Jaime; Kepha, Stella; Krolewiecki, Alejandro Javier; Li, Hanbin; Giang, Justin; et al.; Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults; Nature Publishing Group; Clinical Pharmacology & Therapeutics; 2024; 9-2024; 1-11 0009-9236 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3424 info:eu-repo/semantics/altIdentifier/doi/10.1002/cpt.3424 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Nature Publishing Group |
publisher.none.fl_str_mv |
Nature Publishing Group |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269582957477888 |
score |
13.13397 |